Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belzutifan + Lenvatinib vs Cabozantinib in Advanced Renal Cell Carcinoma
NCT04586231Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Feb 2021
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 25
01
Overview
A Phase 3 trial of belzutifan in renal cell carcinoma (RCC), sponsored by Merck & Co.. Started Feb 2021; status: active, not recruiting.
02
Drugs
belzutifan
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT04586231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04586231.